New drug HXN6005 tested in healthy volunteers for first time
Knowledge-focused
Recruiting now
This Phase 1 trial tests the safety and tolerability of a single dose of HXN6005 in 32 healthy adults aged 18 to 55. Participants receive either the drug or a placebo and are monitored for side effects and how the drug moves through the body. The study is still recruiting and doe…
Phase: PHASE1 • Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC